Next-gen T-cell vaccine for COVID-19
Part of Infections, Lungs & breathing clinical trials.
This trial tests a new type of COVID-19 vaccine that aims to boost your immune system's T-cells (a part of your immune system that helps fight viruses). It is for healthy adults who have either never had a COVID-19 vaccine or had one at least 6 months ago.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You live in the Philippines.
- You have not had a COVID-19 vaccine in the last 6 months, or you have never had one.
- You have not tested positive for COVID-19 in the last 4 weeks.
- You are not pregnant, breastfeeding, or planning to become pregnant during the trial.
- You are generally healthy and do not have a weakened immune system.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new type of COVID-19 vaccine that is designed to train your immune system to make stronger, longer-lasting protection. You may be able to join if you are 40–64, have already had at least two doses of a mRNA COVID-19 vaccine (Pfizer or Moderna) more than 4 months ago, and are generally healthy.
This trial tests a new type of COVID-19 booster vaccine that targets a protein to help your immune system. It's for people who already had a primary vaccine series and at least one mRNA booster, with the last booster at least 6 months ago.
This study looks at how well a COVID-19 booster works in adults who need long-term medicines that lower immune response. It aims to see whether immunosuppressed people benefit from booster vaccination safely.
This study tests a new antibody medicine for people with COVID-19 who are at high risk of getting very sick. If you qualify, you would receive the study drug or a placebo (inactive substance) to see if it helps you recover without needing to go to the hospital.
This study tests an experimental vaccine designed to protect against chikungunya, a mosquito-borne virus that causes fever and joint pain. The trial will evaluate the vaccine's safety and immune response in healthy adults.
This trial tests a new 23-valent pneumococcal vaccine to see if it safely protects healthy people against pneumonia and other infections caused by pneumococcal bacteria.
Hear when a new Coronavirus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.